business has resulted in the Group ending the year with net cash of £62.5 million 
Advanced Medical Solutions Group plc Annual Report 2017 12 To increase the market share of the Group’s brands globally and to develop 
Advanced Medical Solutions Group plc Annual Report 2017 22 Adjusted operating profit before exceptional items increased 
e Assessing the effectiveness of the risk management processes adopted across the Group
e Ensuring implementation of the Group’s actions and mitigation plans required to manage risk
e Identification, review and management of identified Group strategic risks 
e Assessing the effectiveness of the risk management processes adopted across the Group
Chris Meredith e Managing the Group’s business
e Developing Group strategy for consideration and approval by the Board
With regard to the Group’s financial position, it had cash and cash equivalents at the year-end of £62.5 million (2016: £51.1 million) and was 
in the Annual Report of the Group, provides a detailed review of the business.
e Review internal control policies and procedures for the identification, assessment and reporting of material financial and non-financial risks 
e Review the effectiveness of the Group’s financial reporting 
e Reviewed the annual and half-yearly financial reports and related statements and discussed:
e Reviewed the key risks to the Group and the plans to mitigate these risks
e Scoping and planning: – specifically relating to the year-end audit work: timely provision of the External Audit strategy and timetable to Audit 
e The Board or the Audit Committee reviews the Risk Register at least twice a year;
e The Board monitors the activities of the Group through the management accounts, monthly forecasts and other reports on current activities 
e The Group operates a ‘whistle-blowing’ policy enabling any individual with a concern to approach any of the Non-Executive Directors 
As an AIM quoted company, Advanced Medical Solutions Group plc is not required to comply with the Directors’ Remuneration Report 
The Remuneration Committee (Committee) comprises the three Non-Executive Directors of the Group and the Chairman of the Board as laid 
e Review of proposed 2016 Executive Director and Senior Management Team (SMT) bonus and 
e Review of Executive Director Financial Objectives
e In considering the market positioning of reward elements, account will be taken of the performance of the Group and of each individual 
the 2018 financial year, the Committee determined to only increase the basic salary for the Executive Directors by the cost of living (3%).
significant financial loss for the Company, any Group Company and/or the participant’s Business Unit.
e 50% of each Award is subject to a performance condition based on the growth in the Company’s underlying diluted earnings per share (EPS) 
Executive Directors are required to hold shares worth 100% of pre-tax annual salary in Company shares in compliance with the Executive 
This Plan allows relevant employees to receive up to £30,000 of Company shares by reference to the market value of these 
For the five-year period ending 28 February 2018 the Advanced Medical Solutions Group plc share price has outperformed the FTSE All-Share 
For the five-year period ending 28 February 2018 the Advanced Medical Solutions Group plc Total Shareholder Return (TSR), defined as share 
Company law requires the Directors to prepare Financial Statements for each financial year.
In preparing the Group Financial Statements, International Accounting Standard 1 requires that Directors:
e The Strategic Report and Directors’ Report include a fair review of the development and performance of the business and the position of 
e The Annual Report and Financial Statements, taken as a whole, are fair, balanced and understandable, and provide the information necessary 
e the Financial Statements give a true and fair view of the state of the Group’s and of The Parent Company’s affairs as at 31 December 2017 
e the Group Financial Statements have been properly prepared in accordance with International Financial Reporting Standards (IFRSs) as 
e the Financial Statements have been prepared in accordance with the requirements of the Companies Act 2006.
We have audited the Financial Statements of Advanced Medical Solutions Group plc (the ‘Parent Company’) and its subsidiaries (the ‘Group’) 
e the related Parent Company Financial Statement Notes 1 to 7.
The materiality that we used for the Group Financial Statements was £1.2 million which was determined on the basis of approximately 5% of 
e the Directors’ use of the Going Concern basis of accounting in preparation of the Financial Statements is not appropriate; or 
In preparing the Financial Statements, the Directors are responsible for assessing the Group’s and The Parent Company’s ability to continue 
e the information given in the Strategic Report and the Directors’ Report for the financial year for which the Financial Statements are prepared 
The Financial Statements of Advanced Medical Solutions Group plc (registration number 2867684) on pages 66 to 93 were approved by the 
With regards to the Group’s financial position, it had cash and cash equivalents at the year end of £62.5 million.
e They include no contractual obligations upon the Group to deliver cash or other financial assets that are potentially unfavourable to the 
In compliance with IAS 32 ‘Financial Instruments: Presentation Group’, shares held by the EBT are included in the Consolidated Balance Sheet 
e Amendments to IFRS 2, Classification and Measurement of Share-based Payment T ransactions – effective for accounting periods beginning 
The average monthly number of employees of the Group during the year, including Executive Directors, was as follows:
The Financial Statements of Advanced Medical Solutions Group plc (registration number 2867684) on pages 94 to 98 were approved by the 
Advanced Medical Solutions Group plc reported a profit for the financial year ended 31 December 2017 of £9,523,000 (2016: profit of 
Details on the share capital of the Company are provided in Note 27 on page 88 to the Group’s accounts.
Details on the share-based payments of the Company are provided in Note 29 on pages 89 to 93 in the Notes to the Group’s accounts.
1  To receive the Report of the Directors and the Financial Statements of the Company for the year ended 31 December 2017 (together with 